Stuart Ince

550 citations

21 papers · 291 indexed · h-index 9

Impact in

Oncology
- Cancer-related Molecular Pathways
Molecular Biology
- Fibroblast Growth Factor Research
- Protein Degradation and Inhibitors
- Ubiquitin and proteasome pathways
- PI3K/AKT/mTOR signaling in cancer
- Epigenetics and DNA Methylation

Papers in ⓘ

Molecular Biology 16
- Fibroblast Growth Factor Research 7
- PI3K/AKT/mTOR signaling in cancer 5
- Protein Degradation and Inhibitors 3
- Kruppel-like factors research 2
Oncology 9
- Cancer Treatment and Pharmacology 5
- Cancer-related Molecular Pathways 5

Co-authors: Dominik Mumberg (10 shared papers)Karl Ziegelbauer (10 shared papers)Franz von Nussbaum (7 shared papers)Peter Ellinghaus (9 shared papers)Arne Scholz (7 shared papers)Oliver Politz (5 shared papers)Ulf Bömer (3 shared papers)Mélanie Héroult (5 shared papers)
Journals: Cancer Research (13 papers)International Journal of Cancer (2 papers)Journal of Clinical Oncology (2 papers)Journal of Medicinal Chemistry (1 paper)Molecular Cancer Therapeutics (1 paper)
Partner nations: Germany United States Switzerland

In The Last Decade

Stuart Ince

21 papers receiving 284 citations

Peers

Countries citing papers authored by Stuart Ince

Since Specialization

Citations

This map shows the geographic impact of Stuart Ince's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Stuart Ince with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Stuart Ince more than expected).

Fields of papers citing papers by Stuart Ince

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Stuart Ince. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Stuart Ince. The network helps show where Stuart Ince may publish in the future.

Co-authors

The 25 scholars most cited alongside Stuart Ince, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Stuart Ince Line = papers co-authored together Stuart Ince links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Showing the 20 most-cited of 21 papers — load more, or switch the sort, to bring in the rest.

#	Work
1	Rogaratinib: A potent and selective pan‐FGFR inhibitor with broad antitumor activity in FGFR‐overexpressing preclinical cancer models International Journal of Cancer ·Sylvia Grünewald, Oliver Politz, Sebastian Bender, Mélanie Héroult, Klemens Lustig, Uwe Thuß, Christoph Kneip, Charlotte Kopitz, Dieter Zopf, Marie-Pierre L. Collin, Ulf Boemer, Stuart Ince, Peter Ellinghaus, Dominik Mumberg, Holger Hess‐Stumpp, Karl Ziegelbauer	2019	72
2	Changing for the Better: Discovery of the Highly Potent and Selective CDK9 Inhibitor VIP152 Suitable for Once Weekly Intravenous Dosing for the Treatment of Cancer Journal of Medicinal Chemistry ·Ulrich Lücking, Dirk Kosemund, Niels Böhnke, Philip Lienau, Gerhard Siemeister, Karsten Denner, Rolf Bohlmann, Hans Briem, Ildiko Terebesi, Ulf Bömer, Martina Schäfer, Stuart Ince, Dominik Mumberg, Arne Scholz, Raquel Izumi, Stuart Hwang, Franz von Nussbaum	2021	53
3	BAY 1125976, a selective allosteric AKT1/2 inhibitor, exhibits high efficacy on AKT signaling‐dependent tumor growth in mouse models International Journal of Cancer ·Oliver Politz, Franziska Siegel, Lars Bärfacker, Ulf Bömer, Andrea Hägebarth, William J. Scott, Martin Michels, Stuart Ince, Roland Neuhaus, Kirstin Meyer, Amaury E. Fernández‐Montalván, Ningshu Liu, Franz von Nussbaum, Dominik Mumberg, Karl Ziegelbauer	2016	51
4	Abstract 984: Identification of potent and highly selective PTEFb inhibitor BAY 1251152 for the treatment of cancer: from p.o. to i.v. application via scaffold hops Cancer Research ·Ulrich Luecking, Arne Scholz, Dirk Kosemund, Rolf Bohlmann, Hans Briem, Philip Lienau, Gerhard Siemeister, Ildiko Terebesi, Kirstin Meyer, Katja Prelle, Ray Valencia, Stuart Ince, Franz von Nussbaum, Dominik Mumberg, Karl Ziegelbauer, Michael Brands	2017	26
5	Abstract 3022: BAY 1143572, a first-in-class, highly selective, potent and orally available inhibitor of PTEFb/CDK9 currently in Phase I, shows convincing anti-tumor activity in preclinical models of acute myeloid leukemia (AML) Cancer Research ·Arne Scholz, Thomas Oellerich, Akhtar Hussain, Sarah Lindner, Ulrich Luecking, Annette O. Walter, Peter Ellinghaus, Ray Valencia, Franz von Nussbaum, Dominik Mumberg, Michael Brands, Stuart Ince, Hubert Serve, Karl Ziegelbauer	2016	17
6	Phase I Study of the PTEFb Inhibitor BAY 1251152 in Patients with Acute Myelogenous Leukemia Blood ·Michael Byrne, Mark G. Frattini, Oliver G. Ottmann, Ioannis Mantzaris, Martin Wermke, Daniel J. Lee, Daniel Morillo, Arne Scholz, Stuart Ince, Ray Valencia, Fabrício Henrique Pereira De Souza, Raúl Córdoba	2018	16
7	Phase I dose escalation study of the first-in-class selective PTEFb inhibitor BAY 1251152 in patients with advanced cancer: Novel target validation and early evidence of clinical activity. Journal of Clinical Oncology ·Jennifer R. Diamond, Víctor Moreno, Emerson A. Lim, Raúl Córdoba, Charles L. Cai, Stuart Ince, John Lettieri, Claudia Merz, Ray Valencia, Valentina Boni	2018	10
8	Abstract 1739: Preclinical profile of BAY 1163877 - a selective pan-FGFR inhibitor in phase 1 clinical trial Cancer Research ·Mélanie Héroult, Peter Ellinghaus, Christian Sieg, Dirk Brohm, Sylvia Gruenewald, Marie-Pierre L. Collin, Ulf Boemer, Mario Lobell, Walter Huebsch, Matthias Ocker, Stuart Ince, Andrea Haegebarth, Rolf Jautelat, Holger Hess‐Stumpp, Michael Brands, Karl Ziegelbauer	2014	9
9	Abstract DDT02-02: BAY 1143572: A first-in-class, highly selective, potent and orally available inhibitor of PTEFb/CDK9 currently in Phase I, inhibits MYC and shows convincing anti-tumor activity in multiple xenograft models by the induction of apoptosis Cancer Research ·Arne Scholz, Ulrich Luecking, Gerhard Siemeister, Philip Lienau, Ulf Boemer, Peter Ellinghaus, Annette O. Walter, Ray Valencia, Stuart Ince, Franz von Nussbaum, Dominik Mumberg, Michael Brands, Karl Ziegelbauer	2015	8
10	Abstract 772: Anti-tumor efficacy of the selective pan-FGFR Inhibitor BAY 1163877 in preclinical squamous cell carcinoma models of different origin Cancer Research ·Mélanie Héroult, Matthias Ocker, Charlotte Kopitz, Dieter Zopf, Andrea Hägebarth, Karl Ziegelbauer, Stuart Ince, Peter Ellinghaus	2015	5
11	Abstract 3524: BAY 1238097, a novel BET inhibitor with strong efficacy in hematological tumor models Cancer Research ·Pascale Lejeune, Tatsuo Sugawara, Kathy A. Gelato, Heidrun Ellinger‐Ziegelbauer, Amaury E. Fernández‐Montalván, Norbert Schmees, Stephan Siegel, Hilmar Weinmann, Volker Gekeler, Annette O. Walter, Matthias Ocker, Stuart Ince, Bernard Haendler	2015	5
12	Patient selection using novel RNA-based approaches: Early experience from a phase I study with the pan-FGFR inhibitor BAY 1163877 in patients with urothelial bladder cancer. Journal of Clinical Oncology ·Markus Joerger, Martin Schüler, Philippe A. Cassier, Sandra Hildebrandt, Simone Behre, Corinna Helmbrecht, Stephanie Kerpen, Dirk Zielinski, Stuart Ince, Matthias Ocker, Peter Ellinghaus	2017	4
13	Fibroblast Growth Factor Receptor Signaling in Cancer Biology and Treatment Current Signal Transduction Therapy ·Mélanie Héroult, Peter Ellinghaus, Stuart Ince, Matthias Ocker	2014	3
14	Abstract 4703: The BET inhibitor BAY 1238097 shows efficacy in BRAF wild-type and mutant melanoma models Cancer Research ·Bernard Haendler, Kathy A. Gelato, Laura Schöckel, Tatsuo Sugawara, Pascale Lejeune, Heidrun Ellinger‐Ziegelbauer, Amaury E. Fernández‐Montalván, Simon J. Holton, Stephan Siegel, Mélanie Héroult, Annette O. Walter, Stuart Ince, Matthias Ocker	2016	3
15	Abstract 379: Allosteric AKT1/2-inhibitor BAY 1125976 as potent inhibitor in luminal breast cancer resistant to antihormone therapy Cancer Research ·Oliver Politz, Lars Baerfacker, Stuart Ince, Andrea Haegebarth, Ningshu Liu, Roland Neuhaus, Ulf Boemer, Martin Michels, Karl Ziegelbauer, Dominik Mumberg	2016	2
16	Abstract 2050: BAY 1125976, a highly selective and potent allosteric AKT1/2 inhibitor, for the treatment of cancers with aberrations in the PI3K-AKT-mTOR pathway. Cancer Research ·Oliver Politz, Lars Baerfacker, Stuart Ince, William J. Scott, Roland Neuhaus, Ulf Boemer, Martin Michels, Dominik Mumberg, Franz von Nussbaum, Karl Ziegelbauer, Andrea Haegebarth	2013	2
17	ZK 261991. a novel VEGFR inhibitor for tumor therapy Cancer Research ·Karl‐Heinz Thierauch, Martin Haberey, Holger Hess‐Stumpp, Andreas Huth, Stuart Ince, Martin Krueger, Rolf Bohlmann, Ludwig Zorn, Ulla Moenning, Kirstin Meyer, Andreas Reichel	2007	1
18	Abstract 3685: BAY 1125976, is a selective allosteric AKT1/2 inhibitor with high efficacy in AKT1-mutated cancers Cancer Research ·Oliver Politz, Arne Scholz, Andrea Haegebarth, Ningshu Liu, Lars Baerfacker, Stuart Ince, Roland Neuhaus, Ulf Boemer, Martin Michels, Dominik Mumberg	2014	1
19	Abstract A099: Safety, tolerability, pharmacokinetics, and efficacy of pan-fibroblast growth factor receptor inhibitor rogaratinib in Japanese patients with refractory, locally advanced metastatic solid tumors selected with a novel, mRNA-based patient selection strategy Molecular Cancer Therapeutics ·Makoto Tahara, Shunji Takahashi, Matthias Ocker, Stuart Ince, Hendrik Nogai, Changliang Zhang, Fumiyoshi Sei, Peter Ellinghaus	2018	1
20	Abstract 3738: Use of tumor mRNA expression for patient selection in a phase I study of the pan-fibroblast growth factor receptor inhibitor BAY 1163877 Cancer Research ·Peter Ellinghaus, Matthias Ocker, Sebastian Bender, Christoph Kneip, Stuart Ince, Markus Joerger, Martin Schüler	2017	1

About Stuart Ince

Stuart Ince is a scholar working on Molecular Biology, Oncology, Cancer Research, Pulmonary and Respiratory Medicine and Hematology, having authored 21 papers that have together received 291 indexed citations. Recurring topics across this work include Fibroblast Growth Factor Research (7 papers), Cancer, Hypoxia, and Metabolism (6 papers), Cancer Treatment and Pharmacology (5 papers), Cancer-related Molecular Pathways (5 papers), PI3K/AKT/mTOR signaling in cancer (5 papers), Advanced Breast Cancer Therapies (4 papers), Protein Degradation and Inhibitors (3 papers) and Kruppel-like factors research (2 papers). The work is most often cited by research in Oncology (102 citations), Molecular Biology (208 citations), Hematology (23 citations), Pulmonary and Respiratory Medicine (64 citations) and Organic Chemistry (53 citations). Stuart Ince has collaborated with scholars based in Germany, United States and Switzerland. Frequent co-authors include Dominik Mumberg, Karl Ziegelbauer, Franz von Nussbaum, Peter Ellinghaus, Arne Scholz, Oliver Politz, Ulf Bömer, Mélanie Héroult, Ulf Boemer and Ray Valencia. Their work appears in journals such as Cancer Research, International Journal of Cancer, Journal of Clinical Oncology, Journal of Medicinal Chemistry and Molecular Cancer Therapeutics.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact